U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840080) titled 'OEA and LipiSperse Metabolic Study' on Jan. 22.
Brief Summary: A placebo controlled, single blind, cross-over study evaluating the short-term effect of oleoylethanolamide (OEA) with LipiSperse supplementation on metabolic pathways in healthy participants.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers - Male and Female
Pharmacokinetic Study in Healthy Volunteers
Intervention:
OTHER: Placebo
Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules
DIETARY_SU...